武汉艾必赛生物有限公司推荐Anti-LY3437943 Polyclonal Antibody ,精品抗体

链接：https://www.abinscience.cn/product/34/55906.html

名称：Anti-LY3437943 Polyclonal Antibody

货号：HW328024

种属反应性：General

应用：ELISA, IHC, WB

宿主：Rabbit

同种型：IgG

克隆类型：Polyclonal

免疫原：LY3437943

靶标：LY3437943, LY-3437943, CAS: 2381089-83-2

内毒素水平：Please contact with the lab for this information.

纯化方式：Purified by antigen affinity column.

状态：Liquid

用途范围：仅用于科研

储存：Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

产品介绍：Anti-LY3437943 Polyclonal Antibody (HW328024) 是艾必赛生物（abinScience）推出的兔源多克隆抗体（兔 IgG），靶向 LY3437943（即 Retatrutide，礼来在研 GLP-1R/GIPR/GCGR 三靶点激动剂多肽），可作为Retatrutide 相关药物开发、PK/ADA 方法建立、ELISA/WB/IHC 检测的对照/捕获工具。该抗体以 LY3437943 为免疫原，经抗原亲和柱纯化，以液体形式保存在 0.01M PBS, pH 7.4，含 50% 甘油 + 0.05% Proclin 300 中；频繁使用 2–8°C，长期建议 -20 至 -80°C 避反复冻融（自收货日起 ≤12 个月）。（RUO，仅限科研/非临床用途）

LY3437943（Retatrutide）是礼来开发的胰高血糖素样肽-1 受体（GLP-1R）/葡萄糖依赖性促胰岛素多肽受体（GIPR）/胰高血糖素受体（GCGR）三激动剂，通过同时激活三条代谢通路协同调控食欲、能量消耗与糖脂代谢，目前 III 期临床数据显示其减重与降糖效力优于替尔泊肽（Tirzepatide），被视为下一代代谢疾病重磅分子。作为多肽类药物，Retatrutide 的血药浓度监测（PK）、免疫原性（ADA）评估及作用机制研究均需高特异性抗药抗体/检测抗体支撑，HW328024 以全-length 多肽免疫、亲和纯化获得，适合用于 ELISA（1:2000–1:20000）、WB（1:500–1:2000）、IHC 等方法搭建，是 Retatrutide 临床前与转化研究中配套的科研级试剂。

产品购买联系方式：027-87433958/17302791434

邮箱：info@abinscience.com

参考文献：

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. PMID: 38843460

Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. PMID: 39212900

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. PMID: 39019866

The First Triple Agonist for Antiobesity: Retatrutide. PMID: 39724554

Emerging pharmacotherapies for obesity: A systematic review. PMID: 39952695

Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? PMID: 38687506

What is the pipeline for future medications for obesity? PMID: 38302593

Gut hormones and appetite regulation. PMID: 38511400

Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge. PMID: 41056349

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. PMID: 39761578

Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis. PMID: 41537067

The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities. PMID: 41545327

Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. PMID: 42135195

Weight management treatment in obesity. PMID: 40865172

Triple Agonism Based Therapies for Obesity. PMID: 40741227

The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. PMID: 39481534

Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis. PMID: 39817343

Triple-Hormone-Receptor Agonist Retatrutide for Obesity. PMID: 37888925

Retatrutide: a triple incretin receptor agonist for obesity management. PMID: 37902090

Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases. PMID: 39096466

Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. PMID: 40726454

Contractile effects of retatrutide in isolated mouse atrial preparations. PMID: 40464942

Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials. PMID: 38976545

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. PMID: 41054801

The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. PMID: 40630318

Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? PMID: 37086147

Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions. PMID: 38681750

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. PMID: 40022548

Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss. PMID: 37405802

Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. PMID: 41741376

Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. PMID: 39305981

Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. PMID: 41216380

Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP. PMID: 39868848

详情请咨询 abinScience 亚洲区官方子公司 —— 武汉艾必赛生物技术有限公司
官方网址：【中文】https://www.abinscience.cn

【英文】https://www.abinscience.com

武汉艾必赛生物技术有限公司成立于 2023 年，是 abinScience 在亚洲地区设立的官方全资子公司，全面负责 abinScience 品牌在亚太市场的科研试剂推广、销售及技术支持工作。
依托严格的产品研发体系和国际化的质量管理标准，武汉艾必赛与 AtaGenix、ProteoGenix 等知名品牌保持长期战略合作，现已构建起涵盖抗体、重组蛋白、工具酶、试剂盒、实验耗材在内的多品类供应体系，面向区域内科研机构、高校实验室与生物医药企业，提供稳定、高效、可信赖的产品与服务。
核心业务覆盖：
? 抗体产品（单抗、多抗、重组抗体等）
? 蛋白与多肽试剂（标签蛋白、功能蛋白等）
? 分子与细胞实验相关耗材
? 定制化研发服务（蛋白表达、抗体定制、亲和力成熟等）
? 科研供应链整合与项目配套支持
武汉艾必赛始终秉持“Empowering Bioscience Discovery”的理念，为亚太地区的生命科学研究持续注入高质量动能。